Oral cyclophosphamide monotherapy in advanced resistant ocular cicatricial pemphigoid
The prognosis of advanced OCP in patients is unlikely to be altered by the stepladder approach and step-up strategy. While oral cyclophosphamide can be efficacious for remission induction in resistant and aggressive OCP cases, a step-down strategy employing less potent agents with safer side effect profiles should be contemplated for subsequent treatment.
Authors
- Andrew Dolinko (ORCID: https://orcid.org/0000-0002-4289-8336)
- Peter Y. Chang (ORCID: https://orcid.org/0000-0003-0511-8684)
- Arash Maleki (ORCID: https://orcid.org/0000-0001-5533-9798)
- Tate Valerio (ORCID: https://orcid.org/0009-0006-4283-2683)
- C. Stephen Foster (ORCID: https://orcid.org/0000-0002-6612-5653)
- Hasan Bashir (ORCID: https://orcid.org/0000-0003-4362-1897)
- Yasmin Massoudi (ORCID: https://orcid.org/0009-0000-7166-1090)
- Soheila Asgari
- Stephen D. Anesi
- Allison Richey
Institutions
- Harvard University (US)
- Noor Eye Hospital (IR)
- University of Florida (US)
- Ocular Immunology and Uveitis Foundation (US)
- Massachusetts Eye Research and Surgery Institute (US)
Publication Details
- Journal
- Taiwan Journal of Ophthalmology
- Published
- 2024-11-06
- DOI
- https://doi.org/10.4103/tjo.tjo-d-24-00057
- Primary Topic
- Autoimmune Bullous Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00